Abstract
Objective This study investigated associations between patients’ experiences with anti-obesity medications and weight loss expectations prior to bariatric surgery.
Methods Patients were electronically surveyed with a 31-item questionnaire via email or the patient portal with a primary predictor variable of AOMs pre-surgery. Outcomes included degree of weight loss and weight regain and motivation for seeking surgery.
Results 346 persons were invited to complete the survey. 112 (32.4%) were completed, with 7 excluded due to not answering the AOM question. 73% reported AOM use. Among those who took AOMs prior to seeking bariatric surgery, average weight loss was 13 kg (SD ±10 kg) corresponding to a 4.4 kg/m2 decrease in BMI. Of past AOMs receipients, 87% reported weight regain upon stopping AOMs. Average weight regain was 18 kg (SD 13kg, 126% increase). Patients reported improved longevity and quality of life as motivation for seeking surgery with AOM use history having no effect. Subjects reported an average weight loss goal of 65.8 kg (39% of baseline weight) from bariatric surgery.
Conclusion AOMs were commonly used in those seeking bariatric surgery but motivation for surgery did not differ by AOMs use history. Motivations were most often related to goals for better overall health.
Study Importance Questions
Minimal data exists regarding patients’ experience with anti-obesity medicaitons and whether prior experience with these medications impacts patients’ expectations or goals for bariatric surgery.
This cross-sectional survey investigated the frequency of anti-obesity medication use prior to patients seeking bariatric surgery, finding nearly 3/4ths of patients seeking surgery have previously utilized pharmaceutical weight loss therapies.
This study will ideally spur clinical trials to determine the most effective approach to combination therapy, thus moving obesity treatment to a multimodal approach.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Vanderbilt University Medical Center Institutional Review Board deemed this study minimal risk and thus exempt from institutional review (IRB# 232013)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author Disclosures: “The authors declared no conflict of interest.”
Data Availability
All data produced in the present study are available upon reasonable request to the authors
